Results 101 to 110 of about 30,754 (261)
, 2020 Hypertension is a major risk factor for the development of heart failure with preserved ejection fraction (HFPEF) and blood pressure (BP) in itself is an important marker of prognosis. The association of BP levels, and hemodynamic parameters, measured by
López Jaramillo, Patricio +24 more
core +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundUnderlying inflammation has been increasingly recognized in heart failure with a preserved ejection fraction (HFpEF). In this study we tested the hypothesis that pro‐inflammatory biomarkers are elevated in patients with acutely decompensated ...
Abraham Abernethy +7 more
doaj +1 more source
The Role of Renal Denervation in HFpEF
Journal of Clinical MedicineHeart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous clinical syndrome characterized by signs and symptoms of heart failure despite normal or near-normal ejection fraction. It is a debilitating chronic disease that affects millions of people worldwide, and due to the paucity of evidence-based pharmacological treatments ...
Dawood Jamil +6 more
openaire +2 more sources
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Food Safety and Health, EarlyView.Circadian rhythm disruption impairs metabolic regulation, appetite control, and vascular function, promoting obesity and cardiovascular diseases. Evidence highlights a bidirectional relationship where metabolic disorders further disturb circadian timing.
Ghizal Fatima +4 more
wiley +1 more source
Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF. [PDF]
Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF
Rosano, GMC, Vitale, C, Spoletini, I
core +1 more source
New in the diagnosis of heart failure and management of associated conditions in 2021 ESC guidelines
Heart Vessels and Transplantation, 2021 Oben Baysan +2 more
doaj +1 more source
iMeta, EarlyView.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Interdisciplinary Medicine, EarlyView.Macrophage‐derived S100 calcium‐binding protein A9 (S100A9) promotes the pathological progression of pulmonary arterial hypertension (PAH). S100A9 upregulates the interaction between signal‐transducing adaptor protein 2 and leucine‐rich repeat kinase 2, thereby regulating mitochondria–endoplasmic reticulum (ER) contact.
Chen Gong +15 more
wiley +1 more source
HFpEF treatment: pharmacological therapy
, 2018 Heart failure with preserved ejection fraction (HFpEF) is a diverse syndrome characterized by signs and symptoms of heart failure with relatively preserved ejection fraction.
Maja Cikes, Scott D. Solomon
core +1 more source